We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist
News

Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist

Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist
News

Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The grant will be used to cover R&D expenses for the 12-month period from December 2012 through November 2013 to support further research and clinical development of the Company’s proprietary tissue-based Biopump™ platform technology with respect to the treatment of anemia and hepatitis.

The OCS awards grants to companies from various industries in Israel to foster technological innovations. Recipient selections are based on multiple criteria including the uniqueness of a company's technology, and the potential market it addresses, plus the robustness of the company’s business including financial position, R&D capabilities and management experience.

Under the terms of the OCS grant, MMI will repay the grant in full, plus interest, through royalties on revenue received from commercializing the developed technology. The payment of royalties is contingent on such revenues and, in the absence of such revenues, no royalty payments to the OCS are required.

“We are delighted to have been selected to receive this non-dilutive funding from the Israeli OCS and appreciate the continued support. This is our seventh consecutive grant from the Israeli OCS. These grants have been instrumental in furthering the development of our technology and support us in advancing our clinical trials in the United States and Israel,” stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics.

Advertisement